What role will organ preservation play in oesophageal cancer in 2024?
Guillaume PIESSEN | Julie VEZIANT
Seance of wednesday 17 april 2024 (Journée de Cancérologie : cancers oeso-gastriques)
DOI number : 10.26299/tsbb-ct05/emem.2024.14.07
Abstract
Organ preservation in oesophageal cancer is currently undergoing major changes.
This integrated approach requires close collaboration between surgeons, oncologists, radiologists and nuclear medicine specialists to offer each patient personalised, optimal treatment.
While it is one of the recommended options in cases of locally advanced squamous cell carcinoma of the oesophagus, its place in cases of locally advanced adenocarcinoma of the oesophagus and oeso-gastric junction remains to be clarified, particularly in the recent context of the advent of adjuvant immunotherapy.
Taking into account the characteristics of the patient (operability, patient reported outcomes) and the tumour (histological and molecular type, resectability) and using new tools to assess response to treatment will enable us to better define the contours of this innovative strategy in the coming years.
Guillaume Piessen1,2 MD, PhD and Julie Veziant1,2 MD, PhD
Department of Digestive and Oncological Surgery, Claude Huriez Hospital, Chu Lille, F-59000 Lille, France
This integrated approach requires close collaboration between surgeons, oncologists, radiologists and nuclear medicine specialists to offer each patient personalised, optimal treatment.
While it is one of the recommended options in cases of locally advanced squamous cell carcinoma of the oesophagus, its place in cases of locally advanced adenocarcinoma of the oesophagus and oeso-gastric junction remains to be clarified, particularly in the recent context of the advent of adjuvant immunotherapy.
Taking into account the characteristics of the patient (operability, patient reported outcomes) and the tumour (histological and molecular type, resectability) and using new tools to assess response to treatment will enable us to better define the contours of this innovative strategy in the coming years.
Guillaume Piessen1,2 MD, PhD and Julie Veziant1,2 MD, PhD
Department of Digestive and Oncological Surgery, Claude Huriez Hospital, Chu Lille, F-59000 Lille, France